Donor age-related differences in PBPC mobilization with rHuG-CSF

BACKGROUND: Data on the administration of rHuG-CSF to normal donors <18 yea rs old are very limited. STUDY DESIGN AND METHODS: The results of rHuG-CSF administration to 61 dono rs <18 years old (Group A) were retrospectively evaluated and compared with results from 353 donors greater than or equal to 18 years old (Group B) wh o are included; in the Spanish National Donor Registry. The mean age(range) in Group A and B was 14 (1-17) and 38 (18-71)years, respectively (p<0.001) . The mean dose of rHuG-CSF was 10 <mu>g per kg per day (range, 9-16) durin g a mean of 5 days (range, 4-6). Central venous access was placed more freq uently in younger donors (25% vs. 6%; p<0.001). RESULTS: The mean number of CD34+ cells collected was 7.6 and 6.9 x 10(6) p er kg of donor's body weight in Group A and B, respectively. Fifty-six perc ent of Group A donors needed only one apheresis to achieve 14 x 10(6) CD34 cells per kg versus 39 percent of Group B donors (p = 0.01). Side effects were more common in Group B (71% vs. 41%; p<0.001). CONCLUSION:The administration of rHuG-CSF to donors <18 years old leads to CD34+ cell mobilization in a pattern similar to that observed in adults. Gr eater age was associated with a more frequent requirement for more than one apheresis to achieve a similar number of CD34+ cells.